Technical Analysis for ATNF - 180 Life Sciences Corp.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Crossed Above 20 DMA | Bullish | -9.09% | |
| Pocket Pivot | Bullish Swing Setup | -9.09% | |
| Oversold Stochastic | Weakness | -9.09% | |
| NR7 | Range Contraction | -1.32% |
| Alert | Time |
|---|---|
| 10 DMA Resistance | about 9 hours ago |
| Down 5% | about 9 hours ago |
| Down 3% | about 9 hours ago |
| Down 2 % | about 9 hours ago |
| Down 1% | about 9 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/13/2024
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The Company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Company’s primary platform is a novel program to treat fibrosis using anti-TNF, with its lead program in phase 2b/3 clinical trials.
Sector: Industrials
Industry: Conglomerates
Keywords: Biotechnology Clinical Medicine Disease Immunology Pain Inflammation Inflammatory Diseases Cytokine Fibrosis Human Physiology Tumor Necrosis Factor Animal Physiology
Classification
Sector: Industrials
Industry: Conglomerates
Keywords: Biotechnology Clinical Medicine Disease Immunology Pain Inflammation Inflammatory Diseases Cytokine Fibrosis Human Physiology Tumor Necrosis Factor Animal Physiology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.47 |
| 52 Week Low | 1.31 |
| Average Volume | 132,998 |
| 200-Day Moving Average | 4.65 |
| 50-Day Moving Average | 1.74 |
| 20-Day Moving Average | 1.60 |
| 10-Day Moving Average | 1.58 |
| Average True Range | 0.18 |
| RSI (14) | 43.82 |
| ADX | 22.66 |
| +DI | 30.03 |
| -DI | 15.77 |
| Chandelier Exit (Long, 3 ATRs) | 1.43 |
| Chandelier Exit (Short, 3 ATRs) | 2.01 |
| Upper Bollinger Bands | 1.80 |
| Lower Bollinger Band | 1.40 |
| Percent B (%b) | 0.25 |
| BandWidth | 25.13 |
| MACD Line | -0.07 |
| MACD Signal Line | -0.08 |
| MACD Histogram | 0.0089 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.62 | ||||
| Resistance 3 (R3) | 1.63 | 1.61 | 1.60 | ||
| Resistance 2 (R2) | 1.61 | 1.58 | 1.60 | 1.59 | |
| Resistance 1 (R1) | 1.55 | 1.56 | 1.54 | 1.54 | 1.59 |
| Pivot Point | 1.53 | 1.53 | 1.52 | 1.52 | 1.53 |
| Support 1 (S1) | 1.47 | 1.50 | 1.46 | 1.46 | 1.41 |
| Support 2 (S2) | 1.45 | 1.48 | 1.44 | 1.41 | |
| Support 3 (S3) | 1.39 | 1.45 | 1.40 | ||
| Support 4 (S4) | 1.38 |
